These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
93 related articles for article (PubMed ID: 709565)
1. Monitoring of anthracycline cardiotoxicity. Bristow MR; Mason JW; Daniels JR Cancer Treat Rep; 1978 Oct; 62(10):1607-8. PubMed ID: 709565 [No Abstract] [Full Text] [Related]
2. Clinical and non-invasive assessment of anthracycline cardiotoxicity: perspectives on myocardial protection. Mortensen SA; Aabo K; Jonsson T; Baandrup U Int J Clin Pharmacol Res; 1986; 6(2):137-50. PubMed ID: 3459718 [TBL] [Abstract][Full Text] [Related]
3. Reducing the cardiotoxicity of the anthracyclines. Carlson RW Oncology (Williston Park); 1992 Jun; 6(6):95-100, 104, 107, discussion 107-8. PubMed ID: 1535212 [TBL] [Abstract][Full Text] [Related]
4. Prospective monitoring for anthracycline cardiotoxicity: an introduction. McGuire WP Cancer Treat Rep; 1978 Jun; 62(6):855. PubMed ID: 667858 [No Abstract] [Full Text] [Related]
5. The endomyocardial biopsy. Schneiderman H; Hager WD; Gondos B Ann Clin Lab Sci; 1986; 16(2):134-45. PubMed ID: 3516054 [TBL] [Abstract][Full Text] [Related]
6. Use of the myocardial biopsy to monitor cardiotoxicity. Billingham M Cancer Treat Rep; 1978 Oct; 62(10):1607. PubMed ID: 709564 [No Abstract] [Full Text] [Related]
7. [Anthracycline-induced cardiotoxicity: monitoring and prevention of the lesion]. Orditura M; De Vita F; Ciaramella F; Catalano G Ann Ital Med Int; 1994; 9(4):243-8. PubMed ID: 7893575 [TBL] [Abstract][Full Text] [Related]
8. Overview of cardiac pathology in relation to anthracycline cardiotoxicity. Ferrans VJ Cancer Treat Rep; 1978 Jun; 62(6):955-61. PubMed ID: 352510 [TBL] [Abstract][Full Text] [Related]
9. Monitoring of anthracycline-induced cardiotoxicity. Jannazzo A; Hoffman J; Lutz M Ann Pharmacother; 2008 Jan; 42(1):99-104. PubMed ID: 18094345 [TBL] [Abstract][Full Text] [Related]
10. Guidelines for cardiac monitoring of children during and after anthracycline therapy: report of the Cardiology Committee of the Childrens Cancer Study Group. Steinherz LJ; Graham T; Hurwitz R; Sondheimer HM; Schwartz RG; Shaffer EM; Sandor G; Benson L; Williams R Pediatrics; 1992 May; 89(5 Pt 1):942-9. PubMed ID: 1579408 [TBL] [Abstract][Full Text] [Related]
11. Anthracycline cardiotoxicity in long-term survivors of childhood cancer. Scully RE; Lipshultz SE Cardiovasc Toxicol; 2007; 7(2):122-8. PubMed ID: 17652816 [TBL] [Abstract][Full Text] [Related]
15. [Cardiologic sequelae of cytostatic therapy]. Mladosievivcová B Cas Lek Cesk; 2001 Mar; 140(5):138-41. PubMed ID: 11347200 [TBL] [Abstract][Full Text] [Related]
16. Genotyping the risk of anthracycline-induced cardiotoxicity. Deng S; Wojnowski L Cardiovasc Toxicol; 2007; 7(2):129-34. PubMed ID: 17652817 [TBL] [Abstract][Full Text] [Related]
17. Anthracycline associated cardiac toxicity in children with malignancies. Mohta R; Saxena A; Jain Y; Gupta S; Thavaraj V; Narain S; Arya LS Indian Pediatr; 2002 Jun; 39(6):549-55. PubMed ID: 12084948 [No Abstract] [Full Text] [Related]
18. Anthracycline-induced cardiotoxicity: comparison of recommendations for monitoring cardiac function during therapy in paediatric oncology trials. van Dalen EC; van den Brug M; Caron HN; Kremer LC Eur J Cancer; 2006 Dec; 42(18):3199-205. PubMed ID: 17011186 [TBL] [Abstract][Full Text] [Related]
19. An introduction to the metabolic determinants of anthracycline cardiotoxicity. Menna P; Recalcati S; Cairo G; Minotti G Cardiovasc Toxicol; 2007; 7(2):80-5. PubMed ID: 17652809 [TBL] [Abstract][Full Text] [Related]
20. Cardiac toxicity of adriamycin-DNA complex and rubidazone: evaluation by electrocardiogram and endomyocardial biopsy. Benjamin RS; Mason JW; Billingham ME Cancer Treat Rep; 1978 Jun; 62(6):935-9. PubMed ID: 667871 [No Abstract] [Full Text] [Related] [Next] [New Search]